In a patient with microcephaly, feeding problems and restlessness, moderately increased serum and urine citrulline concentrations were observed. Protein and allopurinol loading did not result in additional indications for a urea cycle defect. The diagnosis of citrullinaemia was made at both the enzyme and DNA level, resulting from a novel mutation in the argininosuccinate synthetase gene. The fact that the patient has not suffered from severe deterioration, and that there were only minor abnormalities in metabolite concentrations, suggests that the argininosuccinate synthetase capacity was less affected in vivo than in vitro. In vitro nuclear magnetic resonance investigation suggested an active acetylation mechanism for citrulline. This case illustrates the importance of performing extensive biochemical and molecular investigations in order to reach a de nitive diagnosis, particularly in instances of moderate citrullinaemia.
Introduction
In the majority of cases, increased concentration of citrulline in body £uids is caused by a defect in the urea cycle enzyme argininosuccinate synthetase (ASS; EC 6.3.4.5). 1 However, high serum citrulline concentrations have also been observed in some patients with argininosuccinic aciduria, saccharopinuria and pyruvate carboxylase de¢ciency.
Argininosuccinate synthetase catalyses the generation of argininosuccinate from its substrates citrulline and aspartate in an ATP-dependent reaction in the cytosol and it forms one of the catalytic steps of the urea cycle. The gene coding for ASS in humans is located on chromosome 9q34, and the enzyme consists of four identical subunits. 1 De¢ciency of ASS usually results in hypercitrullinaemia, hypercitrullinuria and hyperammonaemia. Orotic aciduria and hyperglutaminaemia are non-speci¢c additional abnormalities. Increased serum concentrations of citrulline, from 300 to higher than 3000 mmol/L, are found in most ASS-de¢cient patients. 1,2^4 Symptoms and age of onset vary greatly, with most patients su¡ering from mental retardation together with episodes of lethargy or coma. 1, 2 The neonatal type has an often fatal course whilst the late-onset type is frequently associated only with relatively mild mental retardation. Some patients have been described with abnormalities of hair (pili torti) and skin. 5, 6 The intrafamilial phenotype can show great variety. 7 In addtion, asymptomatic patients with citrullinaemia have been described. 8 Patients with citrullinaemia have been classi¢ed biochemically into three groups on the basis of residual ASS activity, enzyme kinetics and tissue speci¢city of the de¢ciency. 9 Following the recent report of Kobayashi et al., 10 who identi¢ed the citrin gene responsible for adult-onset type II citrullinaemia, citrullinaemia can now be classi¢ed into classical citrullinaemia (CTLN1 type I and type III: OMIM #215700, abnormality in ASS gene) and adult-onset type II citrullinaemia (CTLN2: OMIM #603471, abnormality in SLC25A13 gene located on chromosome 7q21.3). Type I patients with CTLN1 are characterized by a ubiquitous de¢ciency of ASS with abnormal kinetics of the residual ASS activity. 11^13 In patients with citrullinaemia type III, also involved in CTLN1, no ASS activity is detectable in liver, kidney and ¢broblasts. 13, 14 The pathogenesis of most CTLN1 patients has been clari¢ed at the molecular level. 14^20 Type I appears to be caused by missense mutations, while type III is mainly caused by abnormal splicing of the ASS gene. 14, 17, 18 On the other hand, in CTLN2 only the hepatic ASS activity is a¡ected whilst the ASS enzyme has normal kinetic features. 9, 11, 12 In patients with CTLN2, serum arginine concentrations are increased as well as citrulline concentrations. 21 Furthermore, argininosuccinic acid is excreted in the urine. 22 Establishment of the DNA diagnosis for citrin de¢ciency in CTLN2 revealed that SLC25A13 mutations are also the molecular cause of a particular type of neonatal hepatitis: neonatal intrahepatic cholestasis caused by citrin de¢ciency: NICCD, OMIM #605814. 23^26 In individuals with this condition, serum concentrations of citrulline as well as of some other amino acids such as threonine, tyrosine and methionine are observed. 23, 25, 26 Most recently, citrin was found to be the mitochondrial aspartate glutamate carrier. 27 The pathogenetic mechanism in CTLN2 and in NICCD is still under investigation. 28, 29 Here we present a young patient with only mildly abnormal metabolite concentrations and without acute signs or symptoms characteristic of citrullinaemia. The diagnosis of ASS de¢ciency was established at the enzyme level, and a novel point mutation in exon 14 of the ASS gene was identi¢ed.
Clinical features
The patient was the second daughter of nonconsanguineous Turkish parents, delivered after an uncomplicated pregnancy^the ¢rst child was a healthy girl. At the age of 4 months, she presented with feeding problems and restlessness. The head circumference was normal at birth, but declined from the third percentile from the age of 4 months. Leftsided hypertonia and mild retardation were observed. Magnetic resonance imaging (MRI) revealed rightsided hemiatrophy, secondary to a right-sided, perinatal temporoparietal haemorrhage. An electroencephalogram (EEG) showed hypofunctional and moderate irritative activities.
From the age of 16 months, protein intake of the patient was restricted to about 1¢7 g/kg body weight (bw). No medication was administered until the age of 17 months, when three to four ¢ts a day were observed, after which anti-epileptic therapy was started.
Up to the time of writing (age 4 years) no further deterioration in symptoms has been observed and no additional abnormalities of hair or skin or additional symptoms have appeared.
Materials and methods

Metabolite analysis
Standard procedures have been applied for the investigation of the metabolite composition in urine and serum. Amino acid determination was based on ion exchange column chromatography using lithium bu¡ers. Organic acids were measured quantitatively by gas chromatography/mass spectrometry after extraction with ethylacetate and trimethylsilylation [using N,O-bis-(trimethylsilyl)tri£uoroacetamide (BSTFA) and 1% trimethylchlorosilane]. The purines and pyrimidines were analysed on a reverse-phase high-perfomance liquid chromatography (HPLC) system, applying detection by photodiode array absorbance.
In vitro proton nuclear magnetic resonance (NMR) spectroscopy was performed on urine samples as described previously. 30
Enzyme analysis
Skin ¢broblasts were cultivated in Dulbecco's Modi¢ed Eagle medium. ASS and argininosuccinate lyase (EC 4.3.2.1) activities were measured according to the method described by Su et al. 31 
Mutation analysis
RNA was isolated from skin ¢broblasts as described by Chomczynski and Sacchi. 32 The ¢rst strand cDNA was synthesized from total RNA by using oligo-(dT) 12^18 and M-MuLV reverse transcriptase. Ampli¢cation of cDNA was performed as published previously. 15,17^19 Oligonucleotides SF (¡89 to ¡70 of the ASS mRNA; the nucleotides are numbered by denoting theÀ' residue of the initiation codon as +1) and TB (1275 to 1255 of the ASS mRNA) as the PCR primers were used to amplify the entire coding region of the ASS mRNA. The sequences of SF and TB were: 5'-CTACTG CAGCTGCCACCGCTGCCCGAGCC-3' and 5'-CGTAG GATCCAATTGAGGAGGCCCCAGCTCC-3', respectively. Ampli¢ed cDNA was separated by gel electrophoresis and was extracted from the gel bands by using QIAEX (QIAGEN) prior to subcloning into the TA cloning vector pCRII-TOPO (Invitrogen). Positive clones were sequenced applying the Dye Terminator Cycle Sequencing Labelling kit (PE Applied Biosystems) on an ABI-310 Genetic Analyser (PE Applied Biosystems).
For diagnostic analysis of the novel 1085G4T mutation identi¢ed in the present patient we used the following primer pair: IVS13F (5'-CCTCCCTAGTGG TATCCTGT-3') and IVS14B (5'-GATAGGCTCTGTGCC CAAGT-3'). Restriction fragments were identi¢ed following digestion with HaeIII and electrophoresis on 3% Amplisize agarose gel. DNA containing the wild-type allele gave rise to fragments of 18,92 and 131 base pairs (bp), whilst for DNA containing the mutant allele, the fragments were 110 and 131 bp.
The amino acid sequence of ASS of di¡erent species was deduced from the mRNA sequences stored in the NCBI Genbank (http://www.ncbi.nlm.ni h.gov). The accession numbers used were: NM_054012, M36708, NM_007494, M26198, M21314, M21315, M35237 and M35236.
Results
Metabolite studies
A moderately increased concentration of citrulline was found in both serum and urine (see Table 1 ). Most other amino acids, particularly glutamine, ornithine and arginine, showed concentrations within the reference range in both £uids. The urinary concentrations of alanine and glycine were mildly elevated. By using in vitro proton NMR (see Fig. 1 ), an Nacetylcitrulline content in urine of 518 mmol/mmol creatinine was observed under anormal protein intake, i.e. 3^4 g/kg bw, compared with a trace for control urines (detection limit about 50 mmol/mmol). With this method, a urinary citrulline concentration of 825 mmol/mmol creatinine was observed, which agreed closely with the results of classical amino acid analysis (see Table 1 ). During a moderate protein restriction of 1 ¢ 7 g/kg bw an excretion of 441 and 439 mmol/mmol creatinine for N-acetylcitrulline and citrulline, respectively, were found. In serum, no Nacetylcitrulline could be detected (detection limit about 20 mmol/L). The urinary excretion of organic acids and purines/pyrimidines was normal both before and during protein restriction. Excretion of uracil was only slightly increased in one sample, while orotic acid was undetected. An allopurinol loading test (5 mg/kg bw) did not lead to increased excretion of orotic acid. Concentrations of blood ammonia were not increased after challenging by either a meal or protein loading (1g/kg bw).
During protein restriction, serum citrulline concentrations were always between 200 and 
Enzyme studies
In patient's ¢broblasts no ASS activity was detected (50¢01 mU/mg protein; reference range 0¢44 to 0¢70; nˆ5), while the activity of the reference enzyme argininosucc inate lyase was 2¢0 mU/mg protein compared with a reference range of 1¢6^3¢1mU/mg protein, based on nine observations.
Molecular studies
Reverse transcription polymerase chain reaction of mRNA from the patient, followed by sequence analysis, demonstrated a 1085G4T transversion in exon 14 of the ASS gene. This changes the codon coding for residue 362 of the ASS protein from GGC, which codes for glycine, to GTC, which codes for valine. Digestion with HaeIII of ampli¢ed genomic DNA isolated from the patient's ¢broblasts produced fragments of 131 and 110 bp, indicating that she was homozygous for the mutation. Similar treatment of DNA from the blood cells of both parents gave rise to an additional fragment of 92 bp, indicating that they were heterozygous for the mutation (see Fig. 2 ). No other mutations were found in the coding region of the ASS gene.
Discussion
Biochemical aspects
The absence of ASS activity observed in this patient can easily explain the elevated concentrations of citrulline observed in her body £uids. This decreased enzyme activity resulted from a homozygous mutation in the ASS gene. Both parents were heterozygous for the mutation, indicating that inheritance was autosomal recessive.
The biochemical aspects of our patient are less severe than in most published ASS-de¢cient patients. 2^6,14^20,33,34 The serum citrulline concentration was, at time of diagnosis, 228 and 288 mmol/L. There was no decrease in serum arginine concentration and no increase in ornithine or glutamine concentrations. In diagnostic algorithms serum citrulline levels higher than 1000 mmol/ L have been considered diagnostic for citrullinaemia. 4 The urine citrulline excretion at diagnosis was 607 and 861mmol/mmol creatinine. Together with the serum concentrations, these are at the low end of previously described pathological ranges. The absence of a clear increase in blood ammonia and/or urinary orotic acid as a consequence of protein loading or meal supports the thesis that this metabolic defect is mild in nature. This is the more remarkable since the patient's ¢broblasts contained no detectable ASS activity, probably because the mutated ASS protein in the ¢broblasts was very labile and easily inactivated during cell homogenization. The valine for glycine substitution at position 362 may interfere with the three-dimensional structure of the protein. The deduced amino acid sequences for ASS from several species are now known and the glycine residue at position 362 is highly conserved in four mammals, in yeasts, and in some bacteria (see Fig. 3 ). The human ASS tetramer has not yet been crystallized, but recently the ASS structure from Escherichia coli was described. 35 After comparing the primary sequences of human and E. coli ASS, the authors suggested that any hydrophobic substitution at position 363 would a¡ect the tertiary and/or quaternary structure. The ASS gene in our patient contained a hydrophobic substitution at position 362, which might also have had a similar e¡ect on tertiary and/or quaternary structure.
An additional and mitigating e¡ect against the manifestation of the mutation in our patient may be an adequate mechanism for the prevention of intracellular citrulline accumulation by acetylation of citrulline. In two of her urine samples, the N-acetylcitrulline concentration was as high as 39% and 50% of the total citrulline concentration, which are both higher than previously reported. 36, 37 E¤cient acetylation can act as an alternative mechanism for the removal of nitrogen from the body and such a mechanism might prevent accumulation of citrulline, ammonia and carbamylphosphate. The apparent absence of the latter in our patient is illustrated by the normal results obtained after challenging with allopurinol. Allopurinol inhibits breakdown of orotic acid, produced from carbamyl phosphate, which can accumulate in cases of disturbed urea cycle activity.
Clinical aspects
The frequently described neurological problems in patients with citrullinaemia, such as mental retardation and seizures, and periods of lethargy or coma, 1, [2] [3] [4] [5] [6] 33, 38 were not present in this patient. This may be due to the fact that, so far as we can tell, she has never experienced periods of hyperammonaemia or hypoargininaemia. Very high serum ammonia concentrations have been implicated as the cause of brain damage in patients with citrullinaemia. 1, 34, 38 However, the right-sided hemiatrophy and temporoparietal brain wasting in our patient are probably not directly related to the ASS defect. Perhaps only the restlessness and feeding problems ¢nd their origin in the ASS de¢ciency.
Recently, there has been increasing evidence for involvement of ASS activity in nitric oxide metabolism. 39^41 It is likely that ASS plays an important role in the regulation of intracellular citrulline and arginine concentrations. Both these amino acids are the product and substrate of the nitric oxide synthase reaction, respectively. 39 It may be that the arginine/ citrulline ratio is better balanced in our patient compared with the majority of CTLN1 patients, which may have spared her from brain damage.
Although the symptoms were relatively mild, the application of protein restriction can nevertheless be bene¢cial, particularly during episodes of biochemical deterioration. However, any improvement in quality of life may be limited. 1, 38 
Molecular genetic aspects
We describe a novel missense mutation in exon 14 of the ASS gene, which is the twenty-ninth di¡erent mutation described in this gene. 14^20,42, 43 Kobayashi et al. recently identi¢ed 20 more novel mutations: 16 missense, two nonsense and two deletions (personal communication). No clear hot spots were identi¢ed in the ASS genes of about 90 CTLN1 patients who were studied, although nine mutations in exon 5, seven in exon 12, six in exon 13 and seven in exon 14 have now been identi¢ed. In American and in Mediterranean Caucasians, the G390R mutation is common. 15, 20 Two mutations (IVS6-2A4G and R304W) were frequently found in Japanese patients with CTLN1. 17^19 The diagnostic ¢ndings in the patient described here are consistent with CTLN1. The detection of the mutation in the ASS gene, the biochemical pro¢le and the presenting symptoms exclude citrullinaemia derived from citrin de¢ciency. This case report underlines the importance of investigations at metabolite, enzyme and DNA level, even in disorders such as citrullinaemia, in which biochemical and clinical features are not obvious.
Addendum
After completion of this manuscript, a paper was published outlining the structure of the human ASS gene. It included a case of citrullinaemia caused by the same mutation as was found in our patient. 44 Mildly increased citrulline concentrations but no symptoms were observed. No direct ASS assay on ¢broblasts was performed.
